Haemonetics
242 hedge funds and large institutions have $3.26B invested in Haemonetics in 2022 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 97 increasing their positions, 83 reducing their positions, and 42 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
97% more call options, than puts
Call options by funds: $3.56M | Put options by funds: $1.81M
23% more capital invested
Capital invested by funds: $2.65B → $3.26B (+$604M)
17% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 83
2.9% more ownership
Funds ownership: 97.99% → 100.9% (+2.9%)
6% less funds holding
Funds holding: 257 → 242 (-15)
33% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$185M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$59.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.4M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$14.5M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$46.3M |
| 2 |
BlackRock
New York
|
-$40.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$40M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$23.6M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.8M |
HAE Hedge Fund Activity: Q1 2022 in Review
242 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2022, worth a combined $3.26B — up 23% from $2.65B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of HAE and 28 opened new positions — a net loss of 14 holders — while 83 trimmed existing stakes and 97 added.
The largest buyer was Capital Research Global Investors, adding an estimated $185M. The largest seller was Armistice Capital, exiting entirely with an estimated $46.3M sold.
- 242 institutional investors held Haemonetics (HAE) as of Q1 2022, down from 257 in Q4 2021.
- Funds reported $3.26B of Haemonetics stock for Q1 2022, up 23% quarter-over-quarter.
- 28 funds opened new Haemonetics positions in Q1 2022 and 42 closed out, a net change of -14 holders.
- The largest Haemonetics buyer in Q1 2022 was Capital Research Global Investors, an estimated $185M added.
- The largest Haemonetics seller in Q1 2022 was Armistice Capital, an estimated $46.3M sold.
Based on aggregated 13F filings for Q1 2022.